This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ResMed Management Discusses Q4 2012 Results - Earnings Call Transcript

Accessories also grew strongly, as both large and small HMEs and DMEs are becoming more systematic about resupply and delivery of replenishment supplies to the patients who need them.

Our global growth in Flow Generators this quarter was primarily driven by the high-end devices. Strong sales reflect the benefits of having all of our PAP devices configured on the smaller, quieter and more appealing S9 platform.

In the Americas the S9 AutoSet and the VPAP Adapt, which is an adaptive servo-ventilator did particularly well.

Growth in the Flow Generator segment was also driven by a positive mix shift from basic CPAP to APAP due to the ongoing growth of home sleep testing, as well as, we believe, physician preference to put patients on the AutoSet, which provides more flexible therapy, improves patient comfort and appears to enhance compliance.

The new EasyCare Online Compliance Management system continues to be well received, and we expect to see some solid ongoing uptake from existing, as well as new accounts.

Products and programs which provide superior therapy and better compliance are what bring the most value to the patients, customers and service providers. In other words, across the whole food chain.

Europe continues to be challenging due to difficult macroeconomic environment, although sales were relatively strong in both Germany and the U.K. Despite this challenging economic climate, bilevel, AutoSets CS, which is also our version of the adaptive servo-ventilator in the rest of the world, and the Stellar products all did well in this quarter.

We also believe that great opportunities exist in Europe to address the connection between sleep-disordered breathing and various comorbidities, such as heart disease, diabetes and so on, as well as occupational health and the more compelling economic case and the more -- and the more and more compelling economic case for treating sleep apnea in general.

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs